1. Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II.
- Author
-
Kian-Keong Poh, Chee Tang Chin, Khim Leng Tong, Ko Beng Tan, Julian, Jee Seong Lim, Weixuan Yu, Horack, Martin, Vyas, Ami, Lautsch, Dominik, Ambegaonkar, Baishali, Brudi, Philippe, Gitt, Anselm K., Poh, Kian-Keong, Chin, Chee Tang, Tong, Khim Leng, Tan, Julian Ko Beng, Lim, Jee Seong, and Yu, Weixuan
- Subjects
CORONARY disease ,HEART diseases ,ACUTE coronary syndrome ,CHOLESTEROL - Abstract
Introduction: Dyslipidaemia is a major risk factor for coronary heart disease (CHD). There is a lack of data on the extent of lipid abnormalities and lipid-lowering therapy (LLT) in Singapore.Methods: The Dyslipidemia International Study (DYSIS) II was a multinational observational study of patients with stable CHD and hospitalised patients with an acute coronary syndrome (ACS). A full lipid profile and use of LLT were documented at baseline, and for the ACS cohort, at four months post-hospitalisation.Results: 325 patients were recruited from four sites in Singapore; 199 had stable CHD and 126 were hospitalised with an ACS. At baseline, 96.5% of the CHD cohort and 66.4% of the ACS cohort were being treated with LLT. In both cohorts, low-density lipoprotein cholesterol (LDL-C) levels were lower for the treated than the non-treated patients; accordingly, a higher proportion of patients met the LDL-C goal of < 70 mg/dL (CHD: 28.1% vs. 0%, p = 0.10; ACS: 20.2% vs. 0%, p < 0.01). By the four-month follow-up, a higher proportion of the ACS patients that were originally not treated with LLT had met the LDL-C goal (from 0% to 54.5%), correlating with the increased use of medication. However, there was negligible improvement in the patients who were treated prior to the ACS.Conclusion: Dyslipidaemia is a significant concern in Singapore, with few patients with stable or acute CHD meeting the recommended European Society of Cardiology/European Atherosclerosis Society goal. LLT was widely used but not optimised, indicating considerable scope for improved management of these very-high-risk patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF